Technology
Health
Biotechnology

Sesen Bio

$0.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0546 (-5.67%) Today
-$0.009 (-0.99%) After Hours

Why Robinhood?

You can buy or sell Sesen Bio and other stocks, options, ETFs, and crypto commission-free!

About

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. Read More The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Employees
24
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
74.64M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.20M
High Today
$0.9649
Low Today
$0.886
Open Price
$0.96
Volume
812.87K
52 Week High
$3.50
52 Week Low
$0.6609

Collections

Technology
Health
Biotechnology
Engineering
Therapy
Medical
Cancer Prevention
2014 IPO

News

MarketBeatMar 6

Stock Price, News, & Analysis for Sesen Bio

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grad...

121
BusinessWireMar 4

Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2018. The Company also reported new, preliminary analyses from the Company’s Phase 3 VISTA trial further demonstrating the activity of Vicinium treatment in patients with high-risk non-muscle invasive bladder cancer (NMIBC). “2018 was a yea...

1,318
Simply Wall StFeb 27

Did Business Growth Power Sesen Bio’s Share Price Gain of 175%?

Some Sesen Bio, Inc. (NASDAQ:SESN) shareholders are probably rather concerned to see the share price fall 51% over the last three months. But that doesn’t change the fact that the returns over the last three years have been very strong. Indeed, the share price is up a very strong 175% in that time. After a run like that some may not be surprised to see prices moderate. If the business can perform well for years to come, then the recent drop could be an opportunity. Check out our latest analysis for Sesen B...

63

Earnings

-$0.37
-$0.28
-$0.18
-$0.09
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 15, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.